This article has been withdrawn at the request of the editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lfs.2019.05.080 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring New and Promising Genetic Biomarkers for Evaluating Traumatic Brain Injuries: A Case-Control Study.
Neurochem Res
December 2024
Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Cairo University, Kasr Alainy Street, Cairo, 11562, Egypt.
Article Synopsis
- Traumatic brain injury (TBI) affects around 50 million people yearly, highlighting the need for effective blood-based biomarkers for diagnosis and prognosis.
- Researchers tested four biomarkers (AKT3, GSK-3β, hsa-miR-16-5p, and MALAT-1) in 30 TBI patients and 10 healthy controls, using blood samples over 30 days.
- The study found AKT3, hsa-miR-16-5p, and GSK-3β to be reliable for diagnosing TBI across various severities, while MALAT-1 was particularly useful for severe cases, showing its ability to aid in prognosis for up to 30 days post-injury.
Role of CD64 and myeloperoxidase as biomarkers for early diagnosis of sepsis in pediatric intensive care unit.
Egypt J Immunol
October 2024
Department of Pediatrics, Faculty of Medicine, Beni-Suef University, Beni Suef, Egypt.
Globally, sepsis is the primary cause of death for children. While research conducted on adults has a significant impact on the diagnosis and treatment of sepsis in newborns and young children, there are significant factors that are pertinent to pediatrics as well. This prospective case-control study was conducted during the period from August 2020 to October 2022 after approval by the institutional ethical committee.
View Article and Find Full Text PDFAssessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome.
Sci Rep
July 2024
Clinical Pathology Department, Faculty of Medicine, Minia University Hospitals, Minia University, El-Minya, Egypt.
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme released in response to the drop in cholesterol level occurring in sepsis. Our study aimed to evaluate the prognostic role of serum Proprotein convertase subtilisin/kexin type 9 (PCSK9) level in children with sepsis and severe sepsis.
View Article and Find Full Text PDFThe Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure.
J Clin Med
May 2024
Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
: The clinical impact of the withdrawal of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on all-cause readmission in patients with heart failure remains unknown. : We enrolled a total of 212 consecutive patients who were hospitalized for heart failure and received SGLT2i during their index hospitalization between February 2016 and July 2022. Of these patients, 51 terminated SGLT2i during or after their index hospitalization.
View Article and Find Full Text PDFThe protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial.
Ther Adv Musculoskelet Dis
May 2024
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Windmill Road, Oxford OX3 7LD, UK.
Article Synopsis
- The Severe Psoriatic Arthritis trial aims to evaluate treatment outcomes for newly diagnosed PsA patients with poor prognostic factors using standard csDMARDs, combination therapies, or early biologics.
- This UK multicenter trial includes patients with specific criteria and measures effectiveness through the PsA disease activity score at 24 weeks.
- The study seeks to determine if early intensive therapy can improve patient outcomes, considering the potential cost-effectiveness of short-term biologics followed by methotrexate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!